Shilpa Medicare Limited has informed the Exchange about execution of definitive agreement by Koanna International FZ LLC, UAE a wholly owned subsidiary of Shilpa Medicare Limited with Pharma Pharmaceutical Industries & Biological Products (PPI), a prominent Saudi enterprise

Marquee Jv AnnouncedStrategic Transactions View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹413.35

prior close

₹412.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.7%+3.5% vs market

Pharmaceuticals peers, median of 148sector-1.0%+3.9% vs sector

On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.5

15m

+0.5

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8-0.7+3.5-1.0+3.9

Next day

+2.2-0.9+3.1-1.1+3.3

+2.5+0.4+2.1-0.1+2.6

+1.2+1.3-0.0-0.3+1.5

+1.9+2.3-0.3+0.6+1.3

+1.4+1.6-0.2+0.0+1.4

+2.6+2.0+0.6+0.4+2.2

15d

-0.9+4.2-5.1+2.0-2.9

-7.1-1.0-6.1-2.1-5.0

-12.9+2.6-15.5-2.2-10.6

-17.1-0.4-16.8-5.2-11.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare's wholly owned UAE subsidiary Koanna International FZ LLC has signed a definitive agreement with Saudi Arabia's Pharma Pharmaceutical Industries & Biological Products (PPI) to form a new joint venture company in the Kingdom of Saudi Arabia. The JV will be owned 70% by PPI and 30% by Koanna, and will set up a new pharmaceutical manufacturing facility. The rollout is in two phases: Phase 1 involves Koanna supplying finished formulations in bulk for repackaging at the new facility, and Phase 2 involves full technology transfer from Shilpa for local manufacturing of finished products. Shilpa will also handle the regulatory filings with the Saudi Food and Drug Authority. The company stated the JV is aimed at strengthening Shilpa's global footprint and consolidating its presence in the MENA region, aligned with Saudi Arabia's Vision 2030 goals.

Likely market impact

This is a strategic expansion move for Shilpa Medicare into the Saudi and broader MENA market with a local partner, which could open new revenue streams over the medium term. For shareholders, it signals international growth ambition, though the 30% minority stake means limited financial contribution in the near term and execution and regulatory risks remain.